MX2019006877A - Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares. - Google Patents

Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares.

Info

Publication number
MX2019006877A
MX2019006877A MX2019006877A MX2019006877A MX2019006877A MX 2019006877 A MX2019006877 A MX 2019006877A MX 2019006877 A MX2019006877 A MX 2019006877A MX 2019006877 A MX2019006877 A MX 2019006877A MX 2019006877 A MX2019006877 A MX 2019006877A
Authority
MX
Mexico
Prior art keywords
pregenen
triol
dione derivatives
treatment
ocular conditions
Prior art date
Application number
MX2019006877A
Other languages
English (en)
Inventor
L Edelman Jeffrey
Nehme Alissar
C Malone Thomas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47179019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019006877(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2019006877A publication Critical patent/MX2019006877A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a derivados de 4-pregenen-11-17-21-triol-3,20-diona novedosos, procesos para prepararlos, composiciones farmacéuticas que los contienen y su uso como productos farmacéuticos como moduladores de los receptores de glucocorticoides o mineralocorticoides. La invención se refiere específicamente al uso de estos compuestos y sus composiciones farmacéuticas para tratar trastornos asociados con la modulación del receptor de glucocorticoides o mineralocorticoides.
MX2019006877A 2011-11-11 2014-05-09 Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares. MX2019006877A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558775P 2011-11-11 2011-11-11

Publications (1)

Publication Number Publication Date
MX2019006877A true MX2019006877A (es) 2019-08-22

Family

ID=47179019

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014005679A MX365859B (es) 2011-11-11 2012-11-09 Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares.
MX2014005678A MX363669B (es) 2011-11-11 2012-11-09 Composiciones farmaceuticas y metodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona.
MX2019006877A MX2019006877A (es) 2011-11-11 2014-05-09 Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014005679A MX365859B (es) 2011-11-11 2012-11-09 Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares.
MX2014005678A MX363669B (es) 2011-11-11 2012-11-09 Composiciones farmaceuticas y metodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona.

Country Status (24)

Country Link
US (7) US8865691B2 (es)
EP (2) EP2776040B1 (es)
JP (2) JP6158201B2 (es)
KR (2) KR102049615B1 (es)
CN (2) CN104203247B (es)
AR (1) AR088846A1 (es)
AU (3) AU2012335590B2 (es)
BR (2) BR112014011333B1 (es)
CA (3) CA2855929C (es)
CL (2) CL2014001244A1 (es)
CO (2) CO6970598A2 (es)
ES (1) ES2806603T3 (es)
HK (2) HK1200367A1 (es)
IL (2) IL232535B (es)
IN (2) IN2014CN03903A (es)
MX (3) MX365859B (es)
MY (2) MY172227A (es)
PH (2) PH12014501078A1 (es)
RU (2) RU2688159C2 (es)
SG (3) SG11201402225RA (es)
TW (1) TWI584809B (es)
UA (2) UA116622C2 (es)
WO (2) WO2013071009A1 (es)
ZA (2) ZA201403430B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
UA121203C2 (uk) * 2013-12-13 2020-04-27 Аллерган, Інк. Спосіб отримання поліморфної форми стероїдоподібної сполуки
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
US20180036233A1 (en) 2015-03-05 2018-02-08 Allergan, Inc. Self-emulsifying drug delivery (sedds) for ophthalmic drug delivery
US20190216726A1 (en) * 2016-09-16 2019-07-18 Kala Pharmaceuticals, Inc. Particles, Compositions and Methods for Ophthalmic and/or Other Applications
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (es) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
US3484436A (en) * 1967-09-07 1969-12-16 Syntex Corp Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids
GB1227992A (es) 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3693032A (en) 1971-04-23 1972-09-19 Ibm Antisaturation technique for ttl circuits
US3984544A (en) * 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS60994B2 (ja) * 1976-07-26 1985-01-11 大正製薬株式会社 プレグナン系化合物の１７α―エステル類の製造法
DE2735110A1 (de) 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
AU777352B2 (en) * 1999-10-15 2004-10-14 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Novel fusidic acid derivatives
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
CN1678306A (zh) * 2002-08-29 2005-10-05 贝林格尔·英格海姆药物公司 在炎性、变应性和增生性疾病中用作糖皮质激素模拟物的3－(磺酰氨基乙基)－吲哚衍生物
JP2005008596A (ja) * 2003-06-20 2005-01-13 Kobayashi Pharmaceut Co Ltd 眼科用組成物
JP2008500282A (ja) * 2004-04-08 2008-01-10 レットメッド ピーティーワイ リミテッド 眼症状の治療
BRPI0513243B8 (pt) * 2004-07-12 2021-05-25 Allergan Inc composições oftálmicas e respectivos usos
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
EP2322183B1 (en) 2006-06-01 2014-10-22 Santen SAS Use of prodrugs for ocular intravitreous administration
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2009053880A (ja) 2007-08-27 2009-03-12 Sony Broadband Solution Corp 情報処理装置、ならびにｃｐｕユニット
US8524697B2 (en) * 2007-12-21 2013-09-03 Merck Sharp & Dohme Corp. C20-C21 substituted glucocorticoid receptor agonists
EP3650017A1 (en) * 2008-06-26 2020-05-13 Anterios, Inc. Dermal delivery
UA116622C2 (uk) * 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей

Also Published As

Publication number Publication date
EP2776041A1 (en) 2014-09-17
JP6216719B2 (ja) 2017-10-18
US20150057258A1 (en) 2015-02-26
US10188667B2 (en) 2019-01-29
US9433631B2 (en) 2016-09-06
ES2806603T3 (es) 2021-02-18
NZ624919A (en) 2016-10-28
RU2688159C2 (ru) 2019-05-20
IL232535B (en) 2019-09-26
MX2014005678A (es) 2014-12-10
US8906892B2 (en) 2014-12-09
AU2012335590A1 (en) 2014-05-29
AU2018200436B2 (en) 2019-10-24
HK1200367A1 (en) 2015-08-07
CL2014001243A1 (es) 2014-11-28
US20130123223A1 (en) 2013-05-16
AU2012335589B2 (en) 2017-08-31
JP6158201B2 (ja) 2017-07-05
IL232534A0 (en) 2014-06-30
TW201325596A (zh) 2013-07-01
EP2776040B1 (en) 2020-04-22
US20180147217A1 (en) 2018-05-31
RU2014123472A (ru) 2015-12-20
CO6970598A2 (es) 2014-06-13
AR088846A1 (es) 2014-07-10
CA2991883C (en) 2020-03-10
US10493082B2 (en) 2019-12-03
SG10201603766PA (en) 2016-07-28
PH12014501078B1 (en) 2014-07-28
US8865691B2 (en) 2014-10-21
TWI584809B (zh) 2017-06-01
BR112014011333A2 (pt) 2017-05-02
JP2014533274A (ja) 2014-12-11
WO2013071009A1 (en) 2013-05-16
CA2855290A1 (en) 2013-05-16
IN2014CN03919A (es) 2015-09-04
PH12014501078A1 (en) 2014-07-28
UA116622C2 (uk) 2018-04-25
CA2991883A1 (en) 2013-05-16
ZA201403431B (en) 2016-05-25
JP2014533275A (ja) 2014-12-11
KR20140095549A (ko) 2014-08-01
PH12014501079B1 (en) 2014-07-28
CA2855290C (en) 2017-02-28
MX2014005679A (es) 2014-12-10
ZA201403430B (en) 2016-05-25
CA2855929A1 (en) 2013-05-16
SG11201402225RA (en) 2014-06-27
US20170182062A1 (en) 2017-06-29
IN2014CN03903A (es) 2015-10-16
BR112014011333B1 (pt) 2020-04-28
PH12014501079A1 (en) 2014-07-28
CN104185472A (zh) 2014-12-03
CN104203247A (zh) 2014-12-10
CN104203247B (zh) 2017-06-06
BR112014011341A2 (pt) 2017-05-02
MX365859B (es) 2019-06-18
SG11201402247PA (en) 2014-06-27
IL232535A0 (en) 2014-06-30
CO6970609A2 (es) 2014-06-13
UA111867C2 (uk) 2016-06-24
AU2018200436A1 (en) 2018-02-08
MX363669B (es) 2019-03-29
CA2855929C (en) 2018-03-27
RU2683775C2 (ru) 2019-04-02
KR102049615B1 (ko) 2019-11-28
RU2014123471A (ru) 2015-12-20
KR20140095548A (ko) 2014-08-01
MY172227A (en) 2019-11-18
CN104185472B (zh) 2017-06-13
US20130123226A1 (en) 2013-05-16
CL2014001244A1 (es) 2014-11-14
WO2013071010A1 (en) 2013-05-16
AU2012335590B2 (en) 2017-10-19
NZ624920A (en) 2017-06-30
US20190365786A1 (en) 2019-12-05
US20150005519A1 (en) 2015-01-01
MY182222A (en) 2021-01-18
EP2776040A1 (en) 2014-09-17
HK1200366A1 (en) 2015-08-07
AU2012335589A1 (en) 2014-05-29
US9717743B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
PH12014501079A1 (en) 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
PH12014501891B1 (en) Substituted chroman compounds as calcium sensing receptor modulators
MX357504B (es) Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
MY196317A (en) Estrogen Receptor Modulators
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
IN2015MN00421A (es)
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
TN2011000518A1 (en) Fused imidazole carboxamides as trpv3 modulators
TN2011000517A1 (en) Fused pyrimidineone compounds as trpv3 modulators
TN2011000520A1 (en) Chromane derivatives as trpv3 modulators
TN2011000523A1 (en) Chromenone derivatives as trpv3 antagonists